Focus: Dogwood Therapeutics is a public biotechnology company focused on small molecule development for neurological indications. The company operates at mid-cap scale with 501-1000 employees headquartered in Alpharetta, Georgia.
Profile data last refreshed 14h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Dogwood Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Dogwood Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Dogwood Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Dogwood Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Continued Preclinical Development - thelegaladvocate.com
Dogwood Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Continued Preclinical Development thelegaladvocate.com
DWTX News | DOGWOOD THERAPEUTICS INC (NASDAQ:DWTX) - ChartMill
DWTX News | DOGWOOD THERAPEUTICS INC (NASDAQ:DWTX) ChartMill
Chemo nerve pain patients get 12-week access to non-opioid Halneuron trial - Stock Titan
Chemo nerve pain patients get 12-week access to non-opioid Halneuron trial Stock Titan
Dogwood Therapeutics Announces Commencement of Halneuron® - GlobeNewswire
Dogwood Therapeutics Announces Commencement of Halneuron® GlobeNewswire
Dogwood Therapeutics, Inc. Q1 2026 SEC 10-Q Filing – Financial Statements, Management Discussion, and Risk Factors - Minichart
Dogwood Therapeutics, Inc. Q1 2026 SEC 10-Q Filing – Financial Statements, Management Discussion, and Risk Factors Minichart
Armistice Capital (NASDAQ: DWTX) reports 9.99% Dogwood stake - Stock Titan
Armistice Capital (NASDAQ: DWTX) reports 9.99% Dogwood stake Stock Titan
Showing 6 of 10 news items
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo